Tangeretin

Tangeretin: A Comprehensive Reference

1. Identity and Chemical Characterization

Systematic Name, Synonyms, and Registry

Tangeretin's systematic chemical name is 4′,5,6,7,8-pentamethoxyflavone (also written 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one). Its CAS Registry Number is 481-53-8, and it carries the research synonyms NSC 53909, NSC 618905, and Ponkanetin. According to ChEBI, tangeretin is a pentamethoxyflavone with methoxy groups at positions 4′, 5, 6, 7, and 8 of the flavone backbone. The name "tangeretin" derives directly from the tangerine (Citrus reticulata), from which it was first isolated.

Chemical Class and Structural Features

Tangeretin (4′, 5, 6, 7, 8-pentamethoxyflavone) is a natural polymethoxyflavone (PMF) compound extracted from citrus peel. Polymethoxyflavonoids, containing two or more methoxy groups in their basic structure, are abundantly found in the peel of citrus fruits. The five methoxy substituents distinguish tangeretin from its close structural relative nobiletin (a hexamethoxyflavone), and this pattern of methylation profoundly influences both its lipophilicity and its biological interactions.

Tangeretin is a yellow crystal that is volatile, difficult to dissolve in water, and easily soluble in organic solvents such as ethanol and ether. Its melting point ranges from 153.0 to 157.0 °C, and it presents as a white to almost white powder to crystal in its purified form. The hydrophobic chemical structure of tangeretin results in its poor solubility in the aqueous environment of the gastrointestinal tract and reduces the absorption of tangeretin by intestinal enterocytes.

Natural Sources and Botanical Origin

Tangeretin is a polymethoxyflavone extracted primarily from the peels of citrus fruits like Citrus sinensis and Citrus reticulata. Citrus plants belonging to the Rutaceae family are one of the richest sources of flavonoids, including nobiletin, tangeretin, hesperidin, neohesperidin, rutin, narirutin, naringenin, and quercetin, which are well known for their beneficial pharmacological activities. Tangeretin concentrates overwhelmingly in the outer peel (the flavedo and albedo) rather than the pulp or juice. Dried tangerine peel is rich in polymethoxylated flavones (PMFs) — a class of antioxidant compounds found almost exclusively in citrus peel and present in significantly higher concentrations than in citrus juice or flesh. Tangeretin is a flavonoid found in the peel of citrus fruits where it most likely provides natural resistance to fungi.

Common Preparations and Forms

In both research and commercial supplement contexts, tangeretin is available as a standardized extract from dried citrus peel, as an isolated phytochemical (typically as a yellow-to-white crystalline powder of ≥95–99% purity by HPLC), and as a component of whole-peel preparations. Despite its promising pharmacological activities, tangeretin has limited aqueous solubility and poor bioavailability, significantly hindering its clinical applicability. To overcome these challenges, various nanocarrier systems have been investigated to enhance tangeretin's therapeutic potential, including polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLNs), and nanoemulsions. The process of adding an acetyl group to the existing substance is usually used to get a drug derivative that helps improve the uptake and effectiveness of targeted natural molecules; for this reason, the derivative of tangeretin, 5-AcTMF (5-acetylated tangeretin), has been used in numerous studies.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Tangeretin is not used as an isolated compound in traditional medicine systems; rather, it is one of many active constituents in preparations made from dried citrus peel. Dried citrus peel derived from Citrus reticulata, also called "chenpi" (陈皮), possesses a complex mixture of flavonoids and has a history of traditional use to treat a variety of digestive disorders. Citri Reticulatae Pericarpium (CRP), commonly called Chenpi in Chinese, is most frequently used as a qi-regulating drug in thousands of Chinese medicine prescriptions.

CRP is found mainly in major citrus-producing areas such as Guangdong, Guangxi, Sichuan, Fujian, and Zhejiang Provinces of China. Since thousands of years in China, CRP has been used widely in clinical practice to treat nausea, vomiting, indigestion, anepithymia, diarrhea, cough, and expectoration. Currently, CRP is listed in the Pharmacopoeia of the People's Republic of China.

Citrus reticulata, commonly known as mandarin orange or tangerine, has been valued both as a fruit and for its medicinal properties for centuries, particularly in TCM. Historically, the dried peel of Citrus reticulata, known as "Chen Pi," has been used to support digestion, reduce phlegm, and invigorate the spleen. Its essential oils and flavonoids have been incorporated into various herbal formulations aimed at promoting gastrointestinal comfort and respiratory health.

Ancient herbalists prescribed it to regulate qi (energy), alleviate bloating, and relieve symptoms of indigestion, such as nausea and vomiting. The medicinal peel was also commonly used to reduce phlegm and ease coughs, making it a cherished remedy during cold and flu seasons.

Japanese Kampo Medicine

In Japan, the dried peels obtained from ripe fruits of Citrus reticulata and Citrus unshiu are used as the crude drug "Chinpi" and dried peel from the ripe fruits of Citrus aurantium is used as the crude drug "Touhi." Similarly, dried immature fruits of Citrus aurantium are used as the crude drug "Kijitsu" (The Ministry of Health, Labour and Welfare of Japan, 2016). In all of these Japanese formulations, tangeretin is among the naturally occurring polymethoxyflavones present in the plant material, though it was not identified or isolated as a discrete compound until the modern era.

Scope of Traditional Use

It is critical to note that no traditional medicine system used tangeretin as an isolated molecule. All traditional applications involved whole peel preparations containing a complex matrix of flavonoids, essential oils, pectins, and other phytochemicals. Modern pharmacological studies have demonstrated that CRP has marked bioactivities, especially on the diseases of the digestive and respiratory systems. The extent to which tangeretin specifically accounts for those traditional actions remains a question that modern research continues to investigate.

3. Key Constituents and Active Compounds

As tangeretin is itself a defined molecule rather than a multi-constituent extract, this section addresses its structural relatives found co-occurring in citrus peel and the chemical determinants of its own activity.

The Polymethoxyflavone (PMF) Group

The most prominent citrus PMFs with proven pharmacological effects are tangeretin, nobiletin, 5′-demethylnobiletin, tetramethyl-o-scutellarein, pentamethoxyflavone, tetramethyl-o-isoscutellarein, and sinensetine. Tangeretin is consistently reported as one of the most abundant PMFs in the peel fraction of tangerines and sweet oranges. Studies highlight that Citrus reticulata peels contain bioactive compounds such as hesperidin, nobiletin, and tangeretin, which exhibit antioxidant, anti-inflammatory, and antimicrobial activities.

Role of the Pentamethoxy Pattern

The five methoxy groups at positions 4′, 5, 6, 7, and 8 confer heightened lipophilicity compared with hydroxylated flavones, which facilitates cellular membrane penetration and contributes to the compound's broad cellular access. The versatility of tangeretin stems from its specific arrangement of methoxy groups on the flavone backbone, which allows chemists to strategically modify the molecule, leading to the synthesis of a range of polymethoxyflavones. Researchers have studied whether demethylation metabolites produced in vivo (such as 4′-demethyltangeretin) also carry biological activity.

4. Mechanisms of Action

Anti-Inflammatory Signaling

Tangeretin decreased the production of nitric oxide (NO), prostaglandin E₂ (PGE₂), tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in a dose-dependent manner. Additionally, it inhibited LPS-induced expression of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at the protein level, as well as TNF-α, IL-1β, and IL-6 at the mRNA level in microglial cells.

Tangeretin clearly inhibited LPS-induced phosphorylation of ERK, N-terminal kinase (JNK), and p38. In addition, tangeretin markedly reduced LPS-stimulated phosphorylation of IκB-α and IKK-β, as well as the nuclear translocation of the p65 subunit of pro-inflammatory transcription factor NF-κB.

Further mechanistic study showed that tangeretin suppressed LPS-induced phosphorylation of mitogen-activated protein kinases and Akt. Tangeretin also inhibited nuclear factor-κB by upregulating sirtuin 1 and 5′-adenosine monophosphate-activated protein kinase.

Antioxidant Pathways

Tangeretin inhibited reactive oxygen species production and p47(phox) phosphorylation, while enhancing the expression of heme oxygenase-1 and the DNA binding activity of nuclear factor-erythroid 2-related factor 2 (Nrf2) to the antioxidant response element in LPS-stimulated microglia. Tangeretin can alleviate inflammation and oxidative response by activating the Sesn2/Keap1/Nrf2 pathway.

Anticancer Signaling: Cell Cycle and Apoptosis

Evidence indicates that tangeretin acts through several mechanisms including growth inhibition, induction of apoptosis, autophagy, antiangiogenesis, and estrogenic-like effects.

Recent studies have shown that tangeretin induces cell-cycle G1 arrest and suppresses cyclooxygenase-2 (COX-2) expression. Tangeretin exerts growth-inhibitory activity by suppressing Cdk2 and Cdk4 kinase as well as by elevating p21 and p27 levels. In another study, it reduced COLO205 cell proliferation by arresting cell cycle progression in the G1 phase.

Tangeretin exerts its anticancer properties via apoptosis induction, cell cycle disruption, autophagy induction, and metastasis and angiogenesis inhibition. Furthermore, it modulates signalling pathways, such as the MAPK and Notch signalling pathway and the PI3K/Akt/mTOR signalling pathway, to exert its anticancer properties.

Tangeretin reduced the total level and phosphorylated nuclear level of signal transducer and activator of transcription 3 (Stat3). Results show that tangeretin inhibits the Stat3 signaling pathway and induces cancer stem cell death, indicating that tangeretin may be a potential natural compound that targets breast cancer cells and cancer stem cells (CSCs).

The MAPK (mitogen-activated protein kinase) signaling pathway is an important regulatory pathway for cell cycle regulation and apoptosis, and tangeretin can significantly affect the ERK and p38 pathways and inhibit the phosphorylation of ERK1/2.

Neuroprotective Signaling

The effects of tangeretin are mainly mediated through the inhibition of oxidative and inflammatory pathways via regulating multiple signaling pathways, including c-Jun N-terminal kinase, phosphoinositide 3-kinase, mitogen-activated protein kinase, nuclear factor erythroid-2-related factor 2, extracellular-signal-regulated kinase, and CRE-dependent transcription.

Metabolic Mechanisms

Pretreatment with an AMPK inhibitor significantly abrogated tangeretin-stimulated AS160 phosphorylation, glucose uptake, and GLUT4 translocation from the cytosol to the plasma membrane. Furthermore, disruption of AMPK using siRNA transfection prevented the glucose uptake stimulated by tangeretin.

Angiopoietin-like 3 (ANGPTL3), an essential inhibitor of lipoprotein lipase (LPL) catalytic activity that regulates triglyceride-rich lipoprotein (TGRL) metabolism in plasma, was markedly downregulated by tangeretin. Tangeretin inhibits the mRNA and protein expression of ANGPTL3 by counteracting LXRα-mediated transcriptional activation in hepatic cells, resulting in a restoration of LPL activity, increases in TGRL metabolism, and a reduction in triglyceride levels in circulation.

5. Scientific Evidence by Area of Use

Important caveat on evidence strength: As of the most recent assessment, there are approximately 8 peer-reviewed studies on tangeretin in humans involving a total of approximately 150 participants, covering neuroprotection, anti-cancer activity, and anti-inflammatory activity. The overall evidence strength is rated as Weak. The overwhelming majority of evidence comes from in vitro (cell culture) and in vivo (rodent model) studies. Where human data exist, they are generally small, exploratory, and not replicated in large randomized controlled trials (RCTs). Each area below clearly identifies the type of evidence available.

5.1 Neurological and Neurodegenerative Conditions

Alzheimer's Disease (preclinical): Studies showed that tangeretin supplementation could prevent cognitive deficits in APP/PS1 mice. Notably, tangeretin supplementation alleviated synaptic dysfunction and integrity. In addition, tangeretin supplementation reduced β-amyloid accumulation and β-secretase activity. These findings suggest that dietary supplementation of tangeretin can be considered as a preventive therapy for patients with Alzheimer's disease. This evidence is preclinical only; no clinical trials in Alzheimer's patients have been published.

Parkinson's Disease (preclinical): Tangeretin significantly preserved dopaminergic neurons, improved motor performance on rotarod, reduced lipid peroxidation and neuroinflammation, and maintained striatal dopamine levels in animal models. Tangeretin has the potential to prevent neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease by regulating a variety of signaling pathways, including stress-activated protein kinase, phosphoinositide 3-kinase, mitogen-activated protein kinase, Nrf2, extracellular signal-regulated kinase, CRE-dependent transcription, thus inhibiting oxidative and inflammatory pathways.

Cerebral Ischemia (animal models): Tangeretin significantly decreased brain water content, infarct volume, neurological score, brain edema, and Evans blue leakage. It also significantly down-regulated inflammatory and pro-inflammatory cytokines and oxidative stress parameters in the serum and brain tissue of experimental rats. qRT-PCR data demonstrated that rats treated with tangeretin could significantly suppress IL-1β, TLR-4, TNF-α, IFNG-γ, and IL-6 and boost the expression of TGF-β1 compared with ischemia/reperfusion injury rats.

Neuroinflammation (cell culture): These results support further exploration of the therapeutic potential and molecular mechanism of tangeretin in relation to neuroinflammation and neurodegenerative diseases accompanied by microglial activation. Tangeretin demonstrates efficacy in mitigating oxidative stress, neuroinflammation, and neuronal damage across various neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, cerebral ischemia, and epilepsy. It shows promise in ameliorating cognitive deficits and memory impairments associated with these diseases. All evidence in this domain is preclinical.

5.2 Anticancer Activity

Breadth of cell lines studied (in vitro): Tangeretin has inhibited cancer cell proliferation in human cancer cell lines derived from squamous cell carcinoma, gliosarcoma, leukemia, melanoma, colorectal cancer, gastric carcinoma, lung carcinoma, breast carcinoma, and oral cancer cells.

Ovarian cancer (in vitro/in vivo): An enhanced response of A2780/CP70 and 2008/C13 cisplatin-resistant human ovarian cancer cells was observed with combination treatments of cisplatin and tangeretin. Pretreatment of cells with tangeretin prior to cisplatin treatment synergistically inhibited cancer cell proliferation. This combination was effective in activating apoptosis via caspase cascade as well as arresting cell cycle at G2/M-phase. Phospho-Akt and its downstream substrates, e.g., NF-κB, phospho-GSK-3β and phospho-BAD, were down-regulated upon tangeretin-cisplatin treatment.

Breast cancer (in vitro): Tangeretin inhibited cell proliferation, CSC formation and tumor growth, and modestly induced apoptosis in cancer stem cells. The frequency of a subpopulation with a CSC phenotype (CD44+/CD24-) was reduced by tangeretin.

Prostate cancer (in vitro): Treatment of the prostate cancer PC-3 and LNCaP cell lines with tangeretin resulted in dose- and time-dependent loss of cell viability, with negligible cytotoxicity in peripheral blood mononuclear cells (PBMCs). In addition, tangeretin induced caspase-3-mediated apoptosis in prostate cancer cells.

Lung cancer (animal model): Compared with a control group, the number of lung tissue tumors in rats treated with ethyl carbamate significantly increased. Compared with the ethyl carbamate group, the MPO activity and ICAM-1 level in the tangeretin-treated group were significantly decreased; the expression levels of the p-JAK, JAK, p-STAT-3, and STAT-3 proteins were significantly decreased; the expression of NF-ĸB was significantly downregulated. The expression of caspase-3 was significantly increased.

Chemotherapy sensitization: Using tangeretin in combination with clinically applied anticancer drugs could be a good strategy for increasing the efficiency of these agents and protecting noncancerous cells from damage caused by chemotherapy. Tangeretin enhances the efficacy of conventional chemotherapy and may overcome drug resistance.

Overall evidence strength: All anticancer evidence remains preclinical (in vitro and animal models). The 2025 comprehensive review advocates for clinical investigations of tangeretin as a complementary cancer therapy, underscoring that no human clinical trials have established efficacy in any cancer indication to date.

5.3 Cardiovascular and Lipid-Modulating Effects

Lipid modulation (in vitro/animal): Findings support the hypothesis that tangeretin exerts a lipid-lowering effect by modulating the LXRα-ANGPTL3-LPL pathway, and thus it can be used as a potential phytochemical for the prevention or treatment of dyslipidemia.

Cardiovascular inflammation and gut microbiota (animal): Tangeretin treatment significantly attenuated the population of CutC-active bacteria, particularly Clostridiaceae and Lactobacillus, induced by choline chloride in rat models. This inhibition led to a decreased efficiency in choline conversion to trimethylamine (TMA), thereby ameliorating cardiovascular inflammation resulting from prolonged choline consumption. Tangeretin's preventive effect against cardiovascular inflammation is intricately linked to its targeted modulation of TMA-producing bacterial activity.

Smooth muscle cells (in vitro): Tangeretin, described in one PubMed-indexed study, inhibited platelet-derived growth factor-BB (PDGF-BB)-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation, a mechanism relevant to atherosclerosis.

Overall evidence strength: Tangeretin and nobiletin show promising cardioprotective effects via lipid lowering, anti-platelet, anti-atherogenic, and antioxidant mechanisms. However, human clinical data are limited; more randomized controlled trials are needed.

5.4 Metabolic Effects: Diabetes and Obesity

Glucose uptake and insulin sensitivity (cell culture and mouse model): Administration of a high-fat diet plus 200 mg/kg of tangeretin significantly altered weight gain, glucose tolerance, total cholesterol levels, and the secretion of adipocytokines such as adiponectin, leptin, resistin, IL-6, and MCP-1. Moreover, AMPK was activated by 200 mg/kg of tangeretin in mouse muscle tissue. These results suggest that tangeretin exerts anti-diabetic effects in both cell culture and mouse models, and these effects are dependent on activating AMPK.

Streptozotocin-induced diabetes (rat model): The altered activities of key enzymes of carbohydrate metabolism such as hexokinase, pyruvate kinase, lactate dehydrogenase, glucose-6-phosphatase, fructose-1,6-bisphosphatase, glucose-6-phosphate dehydrogenase, glycogen synthase, and glycogen phosphorylase in liver of diabetic rats were significantly reverted to near normal levels by the administration of tangeretin. Tangeretin administration improved hepatic glycogen content, suggesting antihyperglycemic potential. The effect produced by tangeretin on various parameters was comparable to that of glibenclamide, a standard oral hypoglycemic drug. These results show that tangeretin modulates hepatic enzyme activities via enhanced secretion of insulin and decreases blood glucose in streptozotocin-induced diabetic rats through its antioxidant potential.

No human clinical trials for diabetes have been published. All current anti-diabetic evidence is preclinical.

5.5 Anti-Inflammatory Effects

The results of mechanistic studies demonstrate that tangeretin possesses a potent anti-inflammatory and antioxidant effect in microglia. Its anti-inflammatory activity has been demonstrated in multiple cell types, including macrophages, microglial cells, and various epithelial and endothelial models, through consistent suppression of NF-κB, MAPK, iNOS, and COX-2 pathways. The results of in vivo and in vitro preclinical studies have highlighted molecular mechanisms and signaling pathways for anti-inflammatory, anti-cancer, chemopreventive, antidiabetic, anti-obesity, hepatoprotective, and neuroprotective effects in neurodegenerative diseases. Human clinical anti-inflammatory trials are absent from the literature as of the time of this writing.

5.6 Hepatoprotective Effects

Treatment with tangeretin ameliorated the deterioration in oxidant/antioxidant status, overpowered neuroinflammation, and ameliorated neurotoxicity-induced apoptosis. This study shows that tangeretin has beneficial effects on cisplatin-induced neurodegeneration. Possible mechanisms underlying these beneficial effects include the antioxidant and anti-inflammatory properties of tangeretin. Separate animal-model studies found that tangeretin alleviated cisplatin-induced acute hepatic injury by targeting MAPKs and apoptosis pathways, as documented in PMC-indexed research.

6. Pharmacokinetics and Bioavailability

Oral Bioavailability

After oral administration of 50 mg/kg body weight tangeretin to rats, the Cmax, Tmax, and t1/2 were 0.87 ± 0.33 μg/mL, 340.00 ± 48.99 minutes, and 342.43 ± 71.27 minutes, respectively. Based on the area under the curves (AUC) of oral and intravenous administration of tangeretin, the calculated absolute oral bioavailability was 27.11%.

In the gastrointestinal tract, maximum concentrations of tangeretin in the stomach and small intestine were found at 4 hours, while in the cecum, colon, and rectum, tangeretin reached the maximum concentrations at 12 hours.

The kinetics of tangeretin were tested by collecting hamster urine and plasma after 35 days of free access to food containing 1% tangeretin. Intestinal absorption of tangeretin was noticeable with respect to the excretion of several metabolites in urine. Animal plasma was almost free of any unchanged tangeretin, indicating extensive first-pass metabolism and metabolite formation.

Despite its health-promoting properties, the application of tangeretin as a potential oral therapeutic agent is greatly attenuated due to its low oral bioavailability.

Bioavailability Enhancement Strategies

Various nanocarrier systems have been investigated to enhance tangeretin's therapeutic potential, including polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLNs), and nanoemulsions, each offering unique advantages in drug delivery and stability. Emulsification has also been explored, though one 28-day sub-acute toxicity study found that the emulsion system did not induce a significant increase in toxicity response.

7. Dosages Reported in Research Studies

The following dosages are reported as used in published peer-reviewed research. No human therapeutic dosage has been established through clinical trials.

• In a rat pharmacokinetic study, 50 mg/kg body weight was administered orally to characterize absorption, distribution, and bioavailability.
• In high-fat diet mouse experiments, 200 mg/kg of tangeretin was administered, which significantly altered weight gain, glucose tolerance, total cholesterol levels, and adipocytokine secretion.
• In a sub-acute 28-day toxicity study in mice, daily low-dose tangeretin administration was evaluated, with the study noting a U-shaped dose–response pattern in regard to hepatic alteration at lower doses.
• In prostate cancer cell studies, the IC₅₀ value of tangeretin on PC-3 cell viability was 17.2 μM, compared with 5.1 μM for 5-acetylated tangeretin (5-ATAN) and 11.8 μM for 5-demethyltangeretin (5-DTAN).

These figures are provided for scientific reference only and derive from preclinical study protocols. No standardized human dosage is established.

8. Safety Considerations and Drug Interactions

General Safety Profile

Tangeretin has a significant advantage over other chemically relevant flavones as it shows large intestinal absorption and is therefore bioavailable. It is also considered safe when administered orally. In oral acute toxicology experiments, high concentrations of tangeretin exposure had no effect on cell viability.

In a sub-acute toxicity evaluation, a 28-day study was conducted comparing tangeretin in emulsion versus an unprocessed oil suspension. The emulsion system did not induce a significant increase in toxicity response. However, the daily low-dose application of tangeretin showed a U-shaped dose–response pattern in regard to hepatic alteration. This U-shaped response at low doses warrants attention in the design of dosing protocols and further study.

CYP Enzyme Interactions

Tangeretin was reported as a potent regioselective stimulator causing CYP3A4 induction. This stimulation can alter midazolam metabolism. Thus, flavonoid food contents should be reported to avoid any unpredictable scenarios. These studies highlight the need for further investigations to confirm the correlation between the in vitro and in vivo results concerning tangeretin-drug interaction.

Efflux Transporter Inhibition and Drug–Drug Interactions

Tangeretin is a potent inhibitor of efflux transporters BCRP, MRP2, and P-gp, and was able to enhance exposure of the drug silybin by inhibiting functions of the barriers mediating transcellular transport. Pharmacokinetic behaviors of silybin in rats were altered by co-administration of tangeretin, in terms of increased AUC and Cmax of silybin compared with silybin given alone. This finding implies that tangeretin may alter the pharmacokinetics of a range of co-administered drugs that are substrates of P-glycoprotein, BCRP, or MRP2 — including numerous oncology drugs, immunosuppressants, and other medications.

Combination with Chemotherapeutics

Tangeretin has inhibited cancer cell proliferation in human cancer cell lines derived from squamous cell carcinoma, gliosarcoma, leukemia, melanoma, colorectal cancer, gastric carcinoma, lung carcinoma, breast carcinoma, and oral cancer cells. Pretreatment of cisplatin-resistant human ovarian cancer cells with tangeretin synergistically enhanced the growth inhibitory effects induced by low-dose cisplatin. While these findings suggest potential benefits in oncology settings, they also imply that tangeretin may unpredictably alter the pharmacodynamics and pharmacokinetics of co-administered chemotherapy agents, which has not been studied in human subjects.

Absence of Human Interaction Data

A fundamental limitation in the safety literature is that essentially all drug-interaction data for tangeretin derive from cell-based or rodent studies. No human pharmacokinetic interaction studies exist. Given its known modulation of CYP3A4 and major efflux transporters, the potential for clinically meaningful interactions with prescription medications cannot be ruled out and has not been formally characterized.

9. Body Systems and Health Areas of Research Interest

• Central Nervous System: Neuroprotection in Alzheimer's, Parkinson's, cerebral ischemia, and epilepsy models; microglial neuroinflammation.
• Cardiovascular System: Lipid modulation, anti-atherogenic and anti-platelet effects, TMAO pathway and gut microbiota modulation in cardiovascular inflammation.
• Oncology: Anti-proliferative and pro-apoptotic activity across a wide range of cancer cell types; chemotherapy sensitization and reversal of drug resistance.
• Endocrine/Metabolic: Anti-diabetic effects via AMPK activation and glucose transporter regulation; anti-obesity effects in high-fat diet rodent models.
• Hepatic System: Hepatoprotection against chemotherapy-induced liver injury; modulation of lipid metabolism enzymes in hepatic cells.
• Immune/Inflammatory System: Suppression of NF-κB, MAPK, iNOS, COX-2, and pro-inflammatory cytokine cascades in multiple cell types.
• Digestive System: Traditional use in citrus peel preparations for nausea, vomiting, indigestion; modern preclinical interest in gut microbiota modulation.

10. Current Research Gaps and Limitations

The results of the studies support the traditional effects of PMFs and therefore it is necessary that these natural compounds be further investigated in clinical trials. A 2025 comprehensive review advocates for clinical investigations of tangeretin as a complementary cancer therapy.

Despite its promising pharmacological activities, tangeretin has limited aqueous solubility and poor bioavailability, significantly hindering its clinical applicability. The hydrophobic structure and extensive first-pass metabolism mean that in vivo concentrations achievable at safe doses may be far lower than those used in cell culture studies, calling into question the direct translation of in vitro findings. The U-shaped dose–response finding in the hepatic safety study further complicates straightforward dose escalation. Finally, the compound's interaction with CYP3A4 and multiple efflux transporters represents an unquantified risk factor in polypharmacy settings that requires systematic human pharmacokinetic investigation.

References

• Agrawal KK, Murti Y. Tangeretin: A Biologically Potential Citrus Flavone. Current Traditional Medicine 2022;8(4):31–41. Bentham Science.
• Arafa EA, Shurrab NT, Buabeid MA. Therapeutic Implications of a Polymethoxylated Flavone, Tangeretin, in the Management of Cancer via Modulation of Different Molecular Pathways. Advances in Pharmacological and Pharmaceutical Sciences 2021. PMC7954633.
• Anticancer Potential of Flavonoids: An Overview with an Emphasis on Tangeretin. PubMed 2023;PMID:37765037.
• Anti-Inflammatory and Antioxidant Mechanism of Tangeretin in Activated Microglia. PubMed 2016;PMID:26899309.
• Tangeretin exerts anti-neuroinflammatory effects via NF-κB modulation in lipopolysaccharide-stimulated microglial cells. PubMed 2014;PMID:24462494.
• Neuroprotective and Anti-inflammatory Effect of Tangeretin Against Cerebral Ischemia-Reperfusion Injury in Rats. PubMed 2020;PMID:32734386.
• An Update on the Potential of Tangeretin in the Management of Neuroinflammation-Mediated Neurodegenerative Disorders. PubMed 2024;PMID:38672774.
• Inhibitory Effects of Tangeretin on Breast Cancer Stem Cell Formation through Suppression of Stat3 Signaling. PubMed 2020;PMID:32503228.
• Tangeretin Sensitizes Cisplatin-resistant Human Ovarian Cancer Cells through Down-regulation of PI3K/Akt Signaling Pathway. PMC3319094.
• Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. PMC5766056.
• Tangeretin's Anti-apoptotic Signaling Mechanisms in Oral Cancer Cells: In Vitro Anti-cancer Activity. PMC10660419. 2023.
• The Lipid-Modulating Effect of Tangeretin on the Inhibition of ANGPTL3 Gene Expression through Regulation of LXRα Activation in Hepatic Cells. PubMed 2021;PMID:34576019.
• Tangeretin stimulates glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat diet-induced obese mice. PubMed 2012;PMID:22476082.
• Effect of tangeretin, a polymethoxylated flavone, on glucose metabolism in streptozotocin-induced diabetic rats. PubMed 2014;PMID:24629597.
• Pharmacokinetics, bioavailability, tissue distribution and excretion of tangeretin in rat. PubMed 2018;PMID:29567257.
• Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies. PubMed 2017;PMID:28958806.
• Hesperidin, nobiletin, and tangeretin are collectively responsible for the anti-neuroinflammatory capacity of tangerine peel (Citri reticulatae pericarpium). Food and Chemical Toxicology 2014.
• Safety evaluation of tangeretin and the effect of using emulsion-based delivery system: Oral acute and 28-day sub-acute toxicity study using mice. Food Research International 2015.
• Tangeretin Alleviates Cisplatin-Induced Acute Hepatic Injury in Rats: Targeting MAPKs and Apoptosis. PMC4816535.
• Tangeretin Mitigates Trimethylamine Oxide Induced Arterial Inflammation by Disrupting Choline–Trimethylamine Conversion through Specific Manipulation of Intestinal Microflora. PMC10975794. 2024.
• Tangeretin alleviates inflammation and oxidative response induced by spinal cord injury by activating the Sesn2/Keap1/Nrf2 pathway. PubMed 2024;PMID:39054118.
• Tangeretin, a natural flavonoid with promising anticancer effects: A comprehensive review. ScienceDirect 2025.
• Progress of Researches on Pharmacological Effects and Bioavailability of Tangeretin. Journal of Oleo Science 2025.
• The Anticancer Perspective of Tangeretin: A Small Review. Molecules 2025;30(2):300.
• Tangeretin – an overview. ScienceDirect Topics.
• Tangeretin — Research & Evidence. SupplementScience.org.
• Acetylation Enhances the Anticancer Activity and Oral Bioavailability of 5-Demethyltangeretin. PMC9658984. 2022.